Explore
Validate
LearnMA5-12150
antibody from Invitrogen Antibodies
Targeting: EPCAM
17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-12150 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- EpCAM Monoclonal Antibody (VU-1D9), Biotin
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- MA5-12150 targets Epithelial Specific Antigen in IHC (P) applications and shows reactivity with Human samples.
- Conjugate
- Biotin
- Antibody clone number
- VU-1D9
- Concentration
- 0.2 mg/mL
Submitted references Plasma Extracellular Vesicles Enriched for Neuronal Origin: A Potential Window into Brain Pathologic Processes.
New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use.
Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential.
Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.
Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition.
Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1.
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
Gene expression patterns in ovarian carcinomas.
Mustapic M, Eitan E, Werner JK Jr, Berkowitz ST, Lazaropoulos MP, Tran J, Goetzl EJ, Kapogiannis D
Frontiers in neuroscience 2017;11:278
Frontiers in neuroscience 2017;11:278
New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use.
Becker TM, Caixeiro NJ, Lim SH, Tognela A, Kienzle N, Scott KF, Spring KJ, de Souza P
International journal of cancer 2014 Jun 1;134(11):2523-33
International journal of cancer 2014 Jun 1;134(11):2523-33
Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential.
Mosoyan G, Nagi C, Marukian S, Teixeira A, Simonian A, Resnick-Silverman L, DiFeo A, Johnston D, Reynolds SR, Roses DF, Mosoian A
PloS one 2013;8(1):e55145
PloS one 2013;8(1):e55145
Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.
Bauerschlag D, Bräutigam K, Moll R, Sehouli J, Mustea A, Salehin D, Krajewska M, Reed JC, Maass N, Hampton GM, Meinhold-Heerlein I
Journal of cancer research and clinical oncology 2013 Feb;139(2):347-55
Journal of cancer research and clinical oncology 2013 Feb;139(2):347-55
Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition.
Nasarre P, Gemmill RM, Potiron VA, Roche J, Lu X, Barón AE, Korch C, Garrett-Mayer E, Lagana A, Howe PH, Drabkin HA
Cancer research 2013 Dec 1;73(23):7111-21
Cancer research 2013 Dec 1;73(23):7111-21
Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.
Horio M, Sato M, Takeyama Y, Elshazley M, Yamashita R, Hase T, Yoshida K, Usami N, Yokoi K, Sekido Y, Kondo M, Toyokuni S, Gazdar AF, Minna JD, Hasegawa Y
Annals of surgical oncology 2012 Jul;19 Suppl 3(Suppl 3):S634-45
Annals of surgical oncology 2012 Jul;19 Suppl 3(Suppl 3):S634-45
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1.
Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, Tsui WY, Kong CK, Brunner HG, van Kessel AG, Yuen ST, van Krieken JH, Leung SY, Hoogerbrugge N
Nature genetics 2009 Jan;41(1):112-7
Nature genetics 2009 Jan;41(1):112-7
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM
Oncogene 2005 Feb 3;24(6):1053-65
Oncogene 2005 Feb 3;24(6):1053-65
Gene expression patterns in ovarian carcinomas.
Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O'Dwyer PJ, Fero MJ, Kristensen GB, Borresen-Dale AL, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI
Molecular biology of the cell 2003 Nov;14(11):4376-86
Molecular biology of the cell 2003 Nov;14(11):4376-86
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Formalin-fixed, paraffin-embedded human breast cancer stained with Epithelial Specific Antigen antibody using peroxidase-conjugate and DAB chromogen. Note cell membrane staining of tumor cells.
- Conjugate
- Biotin
